370 related articles for article (PubMed ID: 32075524)
21. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
[No Abstract] [Full Text] [Related]
22. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
[TBL] [Abstract][Full Text] [Related]
23. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors.
Lu X; Yan S; Koral KA; Chen Z
Expert Rev Anticancer Ther; 2021 Sep; 21(9):917-926. PubMed ID: 34142932
[No Abstract] [Full Text] [Related]
24. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
Maghsoomi Z; Emami Z; Malboosbaf R; Malek M; Khamseh ME
BMC Cancer; 2021 May; 21(1):579. PubMed ID: 34016077
[TBL] [Abstract][Full Text] [Related]
25. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Ravaud A; de la Fouchardière C; Caron P; Doussau A; Do Cao C; Asselineau J; Rodien P; Pouessel D; Nicolli-Sire P; Klein M; Bournaud-Salinas C; Wemeau JL; Gimbert A; Picat MQ; Pedenon D; Digue L; Daste A; Catargi B; Delord JP
Eur J Cancer; 2017 May; 76():110-117. PubMed ID: 28301826
[TBL] [Abstract][Full Text] [Related]
26. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Schlumberger M; Jarzab B; Cabanillas ME; Robinson B; Pacini F; Ball DW; McCaffrey J; Newbold K; Allison R; Martins RG; Licitra LF; Shah MH; Bodenner D; Elisei R; Burmeister L; Funahashi Y; Ren M; O'Brien JP; Sherman SI
Clin Cancer Res; 2016 Jan; 22(1):44-53. PubMed ID: 26311725
[TBL] [Abstract][Full Text] [Related]
27. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
Grasic Kuhar C; Lozar T; Besic N; Music Marolt M
Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146
[TBL] [Abstract][Full Text] [Related]
28. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
[TBL] [Abstract][Full Text] [Related]
29. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu J; Shen L; Zhou Z; Li J; Bai C; Chi Y; Li Z; Xu N; Li E; Liu T; Bai Y; Yuan Y; Li X; Wang X; Chen J; Ying J; Yu X; Qin S; Yuan X; Zhang T; Deng Y; Xiu D; Cheng Y; Tao M; Jia R; Wang W; Li J; Fan S; Peng M; Su W
Lancet Oncol; 2020 Nov; 21(11):1500-1512. PubMed ID: 32966811
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
[TBL] [Abstract][Full Text] [Related]
31. The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial.
Huang NS; Wei WJ; Xiang J; Chen JY; Guan Q; Lu ZW; Ma B; Sun GH; Wang YL; Ji QH; Wang Y
Thyroid; 2021 Dec; 31(12):1808-1813. PubMed ID: 34610756
[No Abstract] [Full Text] [Related]
32. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Wells SA; Robinson BG; Gagel RF; Dralle H; Fagin JA; Santoro M; Baudin E; Elisei R; Jarzab B; Vasselli JR; Read J; Langmuir P; Ryan AJ; Schlumberger MJ
J Clin Oncol; 2012 Jan; 30(2):134-41. PubMed ID: 22025146
[TBL] [Abstract][Full Text] [Related]
33. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Robinson BG; Paz-Ares L; Krebs A; Vasselli J; Haddad R
J Clin Endocrinol Metab; 2010 Jun; 95(6):2664-71. PubMed ID: 20371662
[TBL] [Abstract][Full Text] [Related]
34. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
35. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
[TBL] [Abstract][Full Text] [Related]
36. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu J; Shen L; Bai C; Wang W; Li J; Yu X; Li Z; Li E; Yuan X; Chi Y; Yin Y; Lou W; Xu N; Bai Y; Zhang T; Xiu D; Wang X; Yuan Y; Chen J; Qin S; Jia R; Lu M; Cheng Y; Zhou Z; Li J; He J; Su W
Lancet Oncol; 2020 Nov; 21(11):1489-1499. PubMed ID: 32966810
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Brose MS; Nutting CM; Jarzab B; Elisei R; Siena S; Bastholt L; de la Fouchardiere C; Pacini F; Paschke R; Shong YK; Sherman SI; Smit JW; Chung J; Kappeler C; Peña C; Molnár I; Schlumberger MJ;
Lancet; 2014 Jul; 384(9940):319-28. PubMed ID: 24768112
[TBL] [Abstract][Full Text] [Related]
38. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
Kim M; Yoon JH; Ahn J; Jeon MJ; Kim HK; Lim DJ; Kang HC; Kim IJ; Shong YK; Kim TY; Kim BH
Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
[TBL] [Abstract][Full Text] [Related]
39. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
[TBL] [Abstract][Full Text] [Related]
40. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A
Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
